ESMO Conference Coverage
Filter News By:
Featured News
View all
More News
(Yahoo! Finance) Oct 9, 2019 - Verzenio plus fulvestrant significantly extended life to a median of 46.7 months vs. 37.3 months compared to fulvestrant alone. MONARCH 2 showed statistically significant results for women whose disease...
(Yahoo! Finance) Oct 8, 2019 - Adlai Nortye Ltd. announced today at the European Society for Medical Oncology (ESMO) 2019 Congress the first results from a phase 1b neoadjuvant study of AN0025 (previously known as E7046), an...
(Vantage) Oct 2, 2019 - An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.
(Xconomy National) Oct 1, 2019 - The European Society for Medical Oncology meeting has wrapped up in Barcelona, the last major clinical cancer conference until December’s annual ASH meeting for blood diseases. We’ve highlighted a few...
(Northwestern Medicine) Sept 30, 2019 - Genetic-based treatment nearly doubles time without disease progression in metastatic prostate cancer. For the first time, prostate cancer has been treated based on the genetic makeup of the...
(CNN) Sept 30, 2019 - An experimental prostate cancer therapy may change the way patients are treated for the second-deadliest cancer in men. In a "landmark" phase III clinical trial, presented at the European Society of Medical...
(Precision Oncology News) Sept 29, 2019 - In presentations at the annual meeting of the European Society for Medical Oncology in Barcelona on Friday, researchers reported seemingly contradictory results on the utility of tumor mutational...
(Precision Oncology News) Sept 30, 2019 - Two genomics-centered trials in the Netherlands — the Center for Personalized Cancer Treatment (CPCT-02) and Drug Rediscovery Protocol (DRUP) — are demonstrating the potential for finding tumor...
(Elevar Therapeutics) Sept 29, 2019 - Elevar Therapeutics announced data from the ANGEL trial, a randomized phase 3 study of rivoceranib (also known as apatinib) plus best supportive care in patients with gastric or gastroesophageal...
(Immunomedics) Sept 28, 2019 - Immunomedics today presented at the European Society for Medical Oncology (ESMO) Annual Congress interim data from the 100-patient cohort of cisplatin-eligible patients of the Company’s TROPHY-U-01...

OBR Tweets

Apr 16
Early Impressions of IMpower010: What Might This Mean for Immunotherapy in Early-Stage Non-Small Cell Lung Cancer?… https://t.co/MwVpuqeCFN

Dec 06
Stephen Ansell, MD, PhD, of @MayoCancerCare on options for lymphoma patients who are refractory to CAR T-cell treat… https://t.co/0in19JpTFM

Dec 06
@TomBmt133 of @UCSFCancer considers the significance of the IKEMA study #ASH20 https://t.co/hPGQ0EeLgx

Dec 06
@MichaelDJain on immunotherapy treatment trends in the management of aggressive lymphomas @MoffittNews #ASH20 https://t.co/9XpyqMU0X3

Dec 06
Bhavana Bhatnagar, DO, regarding data on racial disparities in the treatment of AML from #ASH20 https://t.co/IWQOcPAupf

Sep 24
Cristina Suárez, MD, of @vallhebron offers opinion on whether the CheckMate 9ER trial is practice-changing #ESMO20 https://t.co/6m8UCjJPxE

Sep 24
Andrew Schmidt, MD, @dr_aschmidt of @DanaFarber regarding the COVID-19 and Cancer Outcomes Study (CCOS) presented a… https://t.co/tbmT0twPFA

Sep 24
Erika Hamilton, MD, @ErikaHamilton9 of @SarahCannonDocs regarding the Phase III monarchE trial presented at #ESMO20 https://t.co/AiqtvpEZ7u

Sep 24
Giuseppe Giaccone, PhD, MD, of @WeillCornell regarding the step 1 results of the Phase III ATALANTE-1 trial in NSCL… https://t.co/D5Su3qEkbb

Sep 24
Pasi A. Jänne, MD, PhD, of @DanaFarber shares data from #ESMO20 investigating mobocertinib https://t.co/idTloLVyBj